Fig. 7: Diminished behavior phenotypes in TgAPPsweOCN mice treated with senescence inhibitors.
a Schematic diagram of experimental design. 6-MO control (LSL-APPswe, n = 10 males) and TgAPPsweOCN mice were treated with Veh (10%PEG 400) (n = 10 males) or DQ (D 5 mg/kg, Q 50 mg/kg, dissolved in 10% PEG 400, once per two weeks) (n = 9 males), starting at age of 3-MO, and then subjected to indicated behavior tests at 6-MO. b OFT: Representative tracing images and quantifications of the total distance and the center duration time were shown. n.s. not significant, *p < 0.05. c EPMT: Representative tracing images and quantifications of the open arm duration time and entries were shown. *p < 0.05, **p < 0.01, ***p < 0.001. d LDT: Quantifications of the time spent in the light room and the number of transitions into the light room were shown. n.s. not significant, *p < 0.05. e TST, f FST, and g SPT were shown. *p < 0.05, **p < 0.01. h–i MWM: the latency to reach the hidden platform during the training period (h), and representative tracing image and quantification of the time spent in the target quadrant, platform crossing time and swim speed (i) were shown. *p < 0.05, **p < 0.01. One-way ANOVA followed by Tukey post hoc test. All data were presented as mean ± SD.
